Thrombophilia screening - At the right time, for the right patient, with a good reason

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue SUPPL. 1, 2010, Pages

  Stegnar, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Pregnancy complications; screening; thromboembolism; thrombophilia

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; FULMINATING PURPURA; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MEDICAL ETHICS; PATIENT SELECTION; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PSYCHOLOGICAL ASPECT; REVIEW; SCREENING TEST; SKIN NECROSIS; SOCIAL ASPECT; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; WARFARIN INDUCED SKIN NECROSIS;

CHILD; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOPHILIA;

EID: 79251621020     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.367     Document Type: Review

References (66)

1. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-62.
2. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47:1597-606.
3. Nicolaides AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005;24:1-26.
4. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009;7(Suppl 1):301-4.
5. Machin SJ. Pros and cons of thrombophilia testing: Cons. J Thromb Haemost 2003;1:412-3.
6. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 2003;361:901-8.
7. Middeldorp S. Thrombophilia and pregnancy complications: Cause or association? J Thromb Haemost 2007;5(Suppl 1): 276-82.
8. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7.
9. Nowak-Gottl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97: 858-62. (Pubitemid 32154265)
10. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, et al. Laboratory testing for thrombophilia in pediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH). Thromb Haemost 2002; 88:155-6.
11. Raffini L. Thrombophilia in children: Who to test, how, when, and why? Hematology Am Soc Hematol Educ Program 2008: 228-35.
12. Anderson DR, Brill-Edwards P, Walker I. Warfarin-induced skin necrosis in 2 patients with protein S deficiency: Successful reinstatement of warfarin therapy. Haemostasis 1992;22:124-8.
13. Edlich RF, Cross CL, Dahlstrom JJ, Long WB 3rd. Modern concepts of the diagnosis and treatment of purpura fulminans. J Environ Pathol Toxicol Oncol 2008;27:191-6.
14. Heit JA. Thrombophilia: Common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program 2007:127-35.
15. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-703.
17. Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol 2007;19:370-6.
18. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of Factor V Leiden mutation. Lancet 1994;344:1453-7.
19. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-3.
20. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptive users and pregnant women? Br Med J 1996;313:1127-30.
21. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: A systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005;94:17-25.
22. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9.
23. Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol 2005;17:113-6.
24. Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008;37:19-30.
25. Selby R, Geerts W. Prevention of venous thromboembolism: Consensus, controversies, and challenges. Hematology Am Soc Hematol Educ Program 2009:286-92.
26. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
27. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9. (Pubitemid 126449270)
28. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-5.
29. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
30. Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD, et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 2005;98:421-4.
31. Ray SA, Rowley MR, Bevan DH, Taylor RS, Dormandy JA. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction. Eur J Vasc Endovasc Surg 1997;13: 363-70.
32. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009;35: 468-77.
33. Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993;69:231-5.
34. Patnaik MM, Moll S. Inherited antithrombin deficiency: A review. Haemophilia 2008;14:1229-39.
35. Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blomback N. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002;99:2271-2.
36. Faioni EM, Franchi F, Asti D, Mannucci PM. Resistance to activated protein C mimicking dysfunctional protein C: Diagnostic approach. Blood Coagul Fibrinolysis 1996;7:349-52.
37. de Moerloose P, Reber G, Bouvier CA. Spuriously low levels of protein C with a Protac activation clotting assay. Thromb Haemost 1988;59:543.
38. Wolf M, Boyer-Neumann C, Martinoli JL, Leroy-Matheron C, Amiral J, Meyer D, et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989;62:1144-5.
39. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993;70:1067-71.
40. Simmonds RE, Ireland H, Lane DA, Zoller B, Garcia de Frutos P, Dahlback B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998;128:8-14.
41. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
42. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-5.
43. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
44. Emadi A, Crim MT, Brotman DJ, Necochea AJ, Samal L, Wilson LM, et al. Analytic validity of genetic tests to identify Factor V Leiden and prothrombin G20210A. Am J Hematol 2010;85:264-70.
45. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
46. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
47. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737-40.
48. Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev 2008;22:93-105.
49. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: Performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003;49: 1608-14.
50. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007;5: 925-30.
51. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008;143:321-35.
52. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005;293: 2352-61.
53. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 2006;91: 695-8.
54. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003;362:523-6.
55. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of Factor V Leiden - cost-effectiveness analysis. Thromb Haemost 2000;84:752-7.
56. van den Belt AG, Hutten BA, Prins MH, Bossuy PM. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - a decision analysis. Thromb Haemost 2000;84:758-63.
57. Tripodi A. Laboratory testing for lupus anticoagulants: A review of issues affecting results. Clin Chem 2007;53:1629-35.
58. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
59. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76: 12-6.
60. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:844S-86S.
61. Carraro P. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med 2003;41:382-91.
62. Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ. Molecular screening for familial hypercholesterolaemia: Consequences for life and disability insurance. Eur J Hum Genet 2008;16:14-7.
63. Green MJ, Botkin JR. ''Genetic exceptionalism'' in medicine: Clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003;138:571-5.
64. Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: Psychological aspects and implications. J Consult Clin Psychol 2002;70:784-97.
65. Lim J, Macluran M, Price M, Bennett B, Butow P. Short- and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns 2004;13:115-33.
66. Cohn DM, Vansenne F, Kaptein AA, De Borgie CA, Middeldorp S. The psychological impact of testing for thrombophilia: A systematic review. J Thromb Haemost 2008;6:1099-104.